Skip to main content
main-content

01.12.2009 | ORIGINAL ARTICLE | Ausgabe 6/2009

Journal of Inherited Metabolic Disease 6/2009

Clinical and biochemical studies in mucopolysaccharidosis type II carriers

Zeitschrift:
Journal of Inherited Metabolic Disease > Ausgabe 6/2009
Autoren:
I. V. D. Schwartz, L. L. C. Pinto, G. Breda, L. Lima, M. G. Ribeiro, J. G. Mota, A. X. Acosta, P. Correia, D. D. G. Horovitz, C. G. G. Porciuncula, E. Lipinski-Figueiredo, A. C. Fett-Conte, R. P. Oliveira Sobrinho, D. Y. J. Norato, A. C. Paula, C. A. Kim, A. R. Duarte, R. Boy, S. Leistner-Segal, M. G. Burin, R. Giugliani
Wichtige Hinweise
Communicating editor: Ed Wraith
Competing interests: None declared
References to electronic databases. Mucopolysaccharidosis type II: OMIM 309900. Fabry disease: OMIM 301500. Iduronate sulfatase: EC 3.1.6.13.

Summary

The aim of the study was to characterize clinically and biochemically mucopolysaccharidosis type II (MPS II) heterozygotes. Fifty-two women at risk to be a carrier, with a mean age of 34.1 years (range 16–57 years), were evaluated through pedigree analysis, medical history, physical examination, measurement of iduronate sulfatase (IDS) activities in plasma and in leukocytes, quantification of glycosaminoglycans (GAGs) in urine, and analysis of the IDS gene. Eligibility criteria for the study also included being 16 years of age or older and being enrolled in a genetic counselling programme. The pedigree and DNA analyses allowed the identification of 40/52 carriers and 12/52 non-carriers. All women evaluated were clinically healthy, and their levels of urinary GAGs were within normal limits. Median plasma and leukocyte IDS activities found among carriers were significantly lower than the values found for non-carriers; there was, however, an overlap between carriers’ and non-carriers’ values. Our data suggests that MPS II carriers show lower plasma and leukocyte IDS activities but that this reduction is generally associated neither with changes in levels of urinary GAGs nor with the occurrence of clinical manifestations.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2009

Journal of Inherited Metabolic Disease 6/2009 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise